Serum levels of chemokines in parkinson's disease

NeuroImmunoModulation

Volumn 18, Issue 4, 2011, Pages 240-244

  Scalzo, Paula ^a   De Miranda, Aline Silva ^a   Guerra Amaral, Débora Cristina ^a   De Carvalho Vilela, Márcia ^a   Cardoso, Francisco ^a   Teixeira, Antonio Lúcio ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Biomarker; Chemokines; Neuroinflammation; Parkinson's disease

Indexed keywords

CHEMOKINE; EOTAXIN; EOTAXIN 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHEMOKINE CCL11; CHEMOKINE CCL24; CHEMOKINE CCL3; CHEMOKINE CXCL10; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 79952819709     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000323779     Document Type: Article

References (30)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
2. Lotharius J, Brundin P: Pathogenesis of Parkinson's disease: dopamine, vesicles and α- synuclein. Nat Rev Neurosci 2002; 3: 932-942.
3. Whitton PS: Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007; 150: 963-976. (Pubitemid 46628616)
4. Przedborski S: Inflammation and Parkinson's disease pathogenesis. Mov Disord 2010; 25:S55-S57.
5. Tangsey MG, McCoy MK, Frank-Cannon TC: Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007; 208: 1-25. (Pubitemid 47603240)
6. Hald A, Lotharius J: Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol 2005; 193: 279-290. (Pubitemid 40616179)
7. Lee JK, Tran T, Tansey MG: Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol 2009; 4: 419-429.
8. Hirsh EC, Hunot E: Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-397.
9. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy- Agid F: Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993; 52: 1-6. (Pubitemid 23026600)
10. Ambrosini E, Aloisi F: Chemokines and glial cells: a complex network in the central nervous system. Neurochem Res 2004; 29: 1017-1038. (Pubitemid 39011351)
11. Rentzos M, Nikolaou C, Andreagou E, Paraskevas GP, Rombos A, Zoga M, Tsoutsou A, Boufidou F, Kapaki E, Vassilopoulous D: Circulating interleukin-15 and RANTES chemokine in Parkinson's disease. Acta Neurol Scand 2007; 116: 374-379. (Pubitemid 350045501)
12. Shimoji M, Pagan F, Healton EB, Mocchetti I: CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease. Neurotox Res 2009; 16: 318-328.
13. Kalkonde YV, Morgan WW, Sigata J, Maffi SK, Condello C, Kuzjel W, Ahuja SS, Ahuja SK: Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration. Brain Res 2007; 1128: 1-11. (Pubitemid 46048622)
14. Brucki SM, Nitrini R, Caramelli P, Bertolucci PH, Okamoto IH: Suggestions for utilization of the mini-mental state examination in Brazil. Arq Neuropsiquiatr 2003; 61: 777-781. (Pubitemid 37236632)
15. Fahn S, Elton R: Unified Parkinson's disease rating scale; in Fahn S, Marsden CD, Caine DB, Goldstein M (eds): Recent developments in Parkinson's disease. Florham Park, Macmillan Health Care Information, 1987, vol 2, pp 153-163.
16. Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
17. Moreira MA, Tilbery CP, Monteiro LP, Teixeira MM, Teixeira AL: Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. Acta Neurol Scand 2006; 114: 109-113. (Pubitemid 44034258)
18. Christo PP, Vilela MC, Bretas TL, Domingues RB, Greco DB, Livramento JA, Teixeira AL: Cerebrospinal fluid levels of chemokines in HIV infected patients with and without opportunistic infection of the central nervous system. J Neurol Sci 2009; 287: 79-83.
19. Kortekaas R, Leenders KL, Van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, Hendrikse NH: Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005; 57: 176-179. (Pubitemid 40179854)
20. Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofrj M: Peripheral cytokines profiles in Parkinson's disease. Brain Behav Immun 2009; 23: 55-63.
21. Mena MA, Yébenes JG: Glial cells as players in Parkinsonism: the 'good,' the 'bad,' and the 'mysterious' glia. Neuroscientist 2008; 14: 544-560.
22. Scalzo P, Kummer A, Cardoso F, Teixeira AL: Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease. J Neuroimmunol 2009; 216: 122-125.
23. Scalzo P, Kummer A, Cardoso F, Teixeira AL: Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci Lett 2010; 468: 56-58.
24. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW: Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999; 100: 34-41. (Pubitemid 29292549)
25. McGeer PL, McGeer EG: The alpha-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease. Exp Neurol 2008; 212: 235-238.
26. Selikhova MV, Kushlinskii NE, Lyubimova NV, Gusev EI: Impaired production of plasma interleukin-6 in patients with Parkinson's disease. Bull Exp Biol Med 2002; 133: 81-83.
27. Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T: Alterations of T lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 2005; 11: 493-498. (Pubitemid 41627840)
28. Carr L, Tucker A, Fernandez-Botran R: The enhancement of T cell proliferation by L -dopa is mediated peripherally and does not involve interleukin-2. J Neuroimmunol 2003; 142: 166-169. (Pubitemid 38368600)
29. Gangemi S, Basile G, Merendino RAM, Epifanio A, Di Pasquale G, Ferlazzo B, Nicita- Mauro V, Morgante L: Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease. Mediators Inflamm 2003; 12: 251-253. (Pubitemid 37297195)
30. Bielekova B, Martin R: Development of biomarkers in multiple sclerosis. Brain 2004; 127: 1463-1478. (Pubitemid 38899400)